1. https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death.
2. Биличенко Т.Н., Чучалин А.Г. Заболеваемость и смертность населения России от острых респираторных вирусных инфекций, пневмонии и вакцинопрофилактика // Терапевтический архив. - 2018. - №01 - С. 22-26. https://doi.org/10.17116/terarkh201890122-26
3. Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18(4):761-76, vii. https://doi.org/10.1016/j.idc.2004.08.003.
4. Forest WA, Timothy LW, Paula P, Julio AR. Mortality diff erences among hospitalized patients with community-acquired pneumonia in three world regions: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respiratory Medicine. 2013;107(7):1101-1111. https://doi.org/10.1016/j.rmed.2013.04.003.
5. Lopardo GD, Fridman D, Raimondo E. Incidence rate of communityacquired pneumonia in adults: a population-based prospective active surveillance study in three cities in South America. BMJ Open. 2018;8:e019439. https://doi.org/10.1136/bmjopen-2017-019439.
6. Rodrigues CMC, Groves H. Community-Acquired Pneumonia in Children: the Challenges of Microbiological Diagnosis. J Clin Microbiol. 2018;56(3):e01318-17. https://doi.org/10.1128/JCM.01318-17
7. Rodrigues CMC. Challenges of Empirical Antibiotic Th erapy for Community-Acquired Pneumonia in Children. Curr Th er Res Clin Exp. 2017;16(84):e7-e11. https://doi.org/10.1016/j.curtheres.2017.01.002.
8. Cillóniz C, Rodríguez-Hurtado D, Torres A. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. Med Sci (Basel). 2018;6(2):35. https://doi.org/10.3390/medsci6020035.
9. Jain S, Self WH, Wunderink RG et al. CDC EPIC Study Team. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015;373(5):415-27. https://doi.org/10.1056/NEJMoa1500245.
10. Ewig S, Birkner N, Strauss R, et al. New perspectives on communityacquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Th orax. 2009;64(12):1062-9. https://doi.org/10.1136/thx.2008.109785.
11. Vila-Corcoles Al, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F; EPIVAC Study Group. Epidemiology of communityacquired pneumonia in older adults: a population-based study. RespirMed. 2009;103(2):309-16. https://doi.org/10.1016/j.rmed.2008.08.006.
12. Rozenbaum MH, Mangen MJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. Vaccine. 2015;33(28):3193-9. https://doi.org/10.1016/j.vaccine.2015.05.001.
13. Wang J, Li F, Tian Z. Role of microbiota on lung homeostasis and diseases. Sci. ChinaLifeSci. 2017;60:1407. https://doi.org/10.1007/s11427-017-9151-1.
14. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. European Respiratory Journal. 2002;20: 20s-27s; https://doi.org/10.1183/09031936.02.00702002
15. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. Th e aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33(7):1065-79. https://doi.org/10.1007/s10096-014-2067-1.
16. Capelastegui A, España PP, Bilbao A, et al. Etiology of communityacquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis. 2012;12:134. https://doi.org/10.1186/1471-2334-12-134.
17. Wuerth BA, Bonnewell JP, Wiemken TL, et al. Trends in Pneumonia Mortality Rates and Hospitalizations by Organism, United States, 2002-2011. Emerging Infectious Diseases. 2016;22(9):1624-1627. https://doi.org/10.3201/eid2209.150680.
18. Boyles TH, Brink A, Calligaro GL, et al. South African guideline for the management of community-acquired pneumonia in adults. J Thorac Dis. 2017;9(6):1469-1502. https://doi.org/10.21037/jtd.2017.05.31.
19. Peto L, Nadjm B, Horby P, et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2014;108(6):326-37. https://doi.org/10.1093/trstmh/tru058.
20. Arnold FW, La Joie AS, Brock GN, et al. Community-Acquired Pneumonia Organization (CAPO) Investigators. Improving out-comes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 2009;169:1515-24. https://doi.org/10.1001/archinternmed.2009.265.
21. Lim WS, Baudouin SV, George RC et al. Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009; 64 Suppl 3:iii1-55. https://doi.org/10.1136/thx.2009.121434.
22. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America., American Th oracic Society. Infectious Diseases Society of America/American Th oracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(2):S27-72. https://doi.org/10.1086/511159.
23. Woodhead M. New guidelines for the management of adult lower respiratory tract infections. European Respiratory Journal. 2011;38:1250-1251. https://doi.org/10.1183/09031936.00105211.
24. Чучалин А.Г., Синопальников А.И., Козлов Р.С., Тюрин И.Е., Рачина С.А. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике (Пособие для врачей) // Клиническая микробиология и антимикробная химиотерапия. - 2010.- Т.12. - №3. - С.186-225.
25. Чучалин А.Г., Синопальников А.И., Козлов Р.С., Авдеев С.Н., Тюрин И.Е., Руднов В.А., Рачина С.А., Фесенко О.В. Российское респираторное общество (РРО) Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии (МАКМАХ) Клинические рекомендации по диагностике, лечению и профилактике тяжёлой внебольничной пневмонии у взрослых // Пульмонология. - 2014. - №4.- С.13-48.
26. http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskierekomendatsii
27. Paediatric Formulary Committee BNF for children 2016-2017. Vol. 12 London: BMJ Group, Pharmaceutical Press and RCPCH Publications; 2016.
28. Sharland M, Butler K, Cant A, et al. OSH manual of childhood infections. The blue book. Oxford: Oxford University Press; 2016.
29. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, Thomson A. British Th oracic Society Standards of Care Committee. Th orax. 2011;66(2):ii1-23. https://doi.org/10.1136/thoraxjnl-2011-200598.
30. Le Saux N, Robinson J. Pneumonia in healthy Canadian children and youth: Practice points for management. Paediatr Child Health. 2011;16(7):417-24.
31. Bradley JS, Byington CL, Shah SS et al. Th e Management of Community-Acquired Pneumonia in Infants and Children Older Th an 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clinical Infectious Diseases. 2011; 53 (7): e25-e76. https://doi.org/10.1093/cid/cir531.
32. Внебольничная пневмония у детей. Клинические рекомендации. - М.: Оригинал-макет, 2015. - 64 с.
33. Amalakuhan B, Echevarria KL, Restrepo MI. Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon. Expert Opin Pharmacother. 2017;18(11):1039-1048. https://doi.org/10.1080/14656566.2017.1340937.
34. Luan Y, Sun Y, Duan S, Zhao P, Bao Z. Pathogenic bacterial profi le and drug resistance analysis of community-acquired pneumonia in older outpatients with fever. J Int Med Res. 2018;46(11):4596-4604 https://doi.org/10.1177/0300060518786915.
35. Ma Jinghua, Liu Gaizhuang, Chai Qiaoli. Pathogens and antibiotic resistance of children with community-acquired pneumonia. Biomedical Research 2017;28(20):8839-8843.
36. Adhikari R, Shrestha S. Prevalence and antibiotic sensitivity profiles of bacteria causing community acquired pneumonia. International Journal of Infectious Diseases. 2016;45(1):81. https://doi.org/10.1016/j.ijid.2016.02.223.
37. Рачина С.А., Козлов Р.С., Дехнич Н.Н., и др. Антибактериальная терапия тяжёлой внебольничной пневмонии у взрослых: обзор рекомендаций и клинические примеры // Архивъ внутренней медицины. -2015. - №3. - С.63-74. https://doi.org/10.20514 / 2226-6704-2015-0-3-63-74.
38. Синопальников А.И. Левофлоксацин: роль и место в лечении инфекций нижних дыхательных путей // Клиническая медицина. - 2016. - №11. - С.851-860. https://doi.org/10.18821/0023-2149-2016-94-11-851-860.
39. Маянский Н.А., Алябьева Н.М., Пономаренко О.А., и др. Ди-
40. намика распространённости серотипов и антибиотикорезистентности носоглоточных пневмококков, выделенных у детей в 2010-2016 гг.: результаты ретроспективного когортного исследования // Вопросы современной педиатрии. -2017. - Т.16. - №5. - С.413-423. https://doi.org/10.15690/vsp.v16i5.1806.
41. Инструкция по медицинскому применению лекарственного препарата Флемоксин Солютаб. Регистрационный номер: ЛС-00185. Доступно на сайте ГЛРС: http://grls.rosminzdrav.ru/grls.aspx.
42. Gidal A, Barnett S. Risk Factors Associated With Multidrug-Resistant Pneumonia in Nonhospitalized Patients. Fed Pract. 2018;35(1):16-18.
43. Aspa J, Rajas O, Rodríguez de Castro F et al. Infectious Diseases in Clinical Practice. 2008;16(6):368-375. https://doi.org/10.1097/IPC.0b013e31817eec69.
44. Postma DF, van Werkhoven CH, VanElden LJR, et al. Antibiotic treatment strategies for community acquired pneumonia in adults. N Engl J Med. 2015;372:1312-1323. https://doi.org/10.1056/NEJMoa1406330.
45. Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs β-Lactam-macrolide combination treatment in moderately severe communityacquired pneumonia: a randomized non-inferiority trial. JAMAInternMed. 2014;174(12):1894-1901. https://doi.org/10.1001/jamainternmed.2014.4887.
46. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. CritCareMed. 2014 Feb;42(2):420-32. https://doi.org/10.1097/CCM.0b013e3182a66b9b.
47. Eljaaly K, Alshehri S, Aljabri A, etal. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with communityacquired pneumonia: a systematic review and meta-analysis. BMC InfectDis. 2017;17(1):385. https://doi.org/10.1186/s12879-017-2495-5.
48. Okumura J, Shindo Y, Takahashi K, et al. Central Japan Lung Study Group Mortality in patients with community-onset pneumonia at low risk of drugresistant pathogens: Impact of β-lactam plus macrolide combination therapy. Respirology. 2018;23(5):526-534. https://doi.org/10.1111/resp.13232.
49. Ambroggio L, Test M, Metlay JP, et al. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia. Pediatr Pulmonol. 2015;51(5):541-8. https://doi.org/10.1002/ppul.23312.
50. Tansarli GS, Mylonakis E. Systematic Review and Meta-analysis of the Effi cacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults. Antimicrobial Agents and Chemotherapy. 2018;62 (9): e00635-18. https://doi.org/10.1128/AAC.00635-18.
51. File TM, Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifl oxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blindstudy. Journal of Antimicrobial Chemotherapy. 2007;60(1):112-120. https://doi.org/10.1093/jac/dkm119.
52. Dunbar LM, Khashab MM, Kahn JB, et al. Effi cacy of 750-mg, 5-day levofl oxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin. 2004;20(4): 555-563. https://doi.org/10.1185/030079904125003304.
53. Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Current Medical Research and Opinion. 2004;20(5):739-747. https://doi.org/10.1185/030079904125003610.
54. Léophonte P, Choutet P, Gaillat J, et al. Effi cacy of a ten day course of ceft riaxone compared to a shortened fi ve day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Medecine et Maladies Infectieuses. 2002;32(7):369-381.
55. Uranga A, España PP, Bilbao A, et al. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. JAMA Intern Med. 2016;176(9):1257-65. https://doi.org/10.1001/jamainternmed.2016.3633.
56. Nascimento-Carvalho AC, Nascimento-Carvalho CM. Clinical management of community-acquired pneumonia in young children. Expert OpinPharmacother. 2019;20(4):435-442. https://doi.org/10.1080/14656566.2018.
57. Nascimento-Carvalho CM, Andrade DC, Vilas-Boas AL. An update on antimicrobial options for childhood community-acquired pneumonia: a critical appraisal of available evidence. ExpertOpinPharmacother. 2016;17(1):53-78. https://doi.org/10.1517/14656566.2016.1109633.
58. Quaak CH, Cové E, Driessen GJ, Tramper-Stranders GA. Trends in paediatric inpatient antibiotic therapy in a secondary care setting. Eur J Pediatr. 2018;177(8):1271-1278. https://doi.org/10.1007/s00431-018-3185-z.